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Background: Negative affective states such as anxiety, depression and stress are significant risk factors for
cardiovascular disease, particularly in cardiac and post-cardiac rehabilitation populations.
Yoga is a balanced practice of physical exercise, breathing control and meditation that can reduce psychosocial
symptoms as well as improve cardiovascular and cognitive function. It has the potential to positively affect multiple
disease pathways and may prove to be a practical adjunct to cardiac rehabilitation in further reducing cardiac risk
factors as well as improving self-efficacy and post-cardiac rehabilitation adherence to healthy lifestyle behaviours.
Method and design: This is a parallel arm, multi-centre, randomised controlled trial that will assess the outcomes
of post- phase 2 cardiac rehabilitation patients assigned to a yoga intervention in comparison to a no-treatment
wait-list control group. Participants randomised to the yoga group will engage in a 12 week yoga program comprising
of two group based sessions and one self-administered home session each week. Group based sessions will be led by
an experienced yoga instructor. This will involve teaching beginner students a hatha yoga sequence that incorporates
asana (poses and postures), pranayama (breathing control) and meditation. The primary outcomes of this study are
negative affective states of anxiety, depression and stress assessed using the Depression Anxiety Stress Scale. Secondary
outcomes include measures of quality of life, and cardiovascular and cognitive function. The cardiovascular outcomes
will include blood pressure, heart rate, heart rate variability, pulse wave velocity, carotid intima media thickness
measurements, lipid/glucose profiles and C-reactive protein assays. Assessments will be conducted prior to (week 0),
mid-way through (week 6) and following the intervention period (week 12) as well as at a four week follow-up (week 16).
Discussion: This study will determine the effect of yoga practice on negative affective states, cardiovascular and
cognitive function in post-phase 2 cardiac rehabilitation patients. The findings may provide evidence to incorporate
yoga into standardised cardiac rehabilitation programs as a practical adjunct to improve the management of
psychosocial symptoms associated with cardiovascular events in addition to improving patients’ cognitive and
cardiovascular functions.
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Cardiovascular disease (CVD) is a leading cause of mor-
bidity and mortality worldwide. In 2004, CVD caused
17.1 million deaths and this is estimated to increase to
23.6 million by 2030 [1]. This increase is paralleled by
an increase in the prevalence of psychological risk fac-
tors such as anxiety, depression, and stress that have
been shown to be associated with CVD morbidity and
mortality [2,3]. Anxiety and depression are common
after CVD events with prevalence rates up to 31%. Inter-
estingly, anxiety and depression in CVD patients appear
to be independent of functional health, time between
cardiac incidents, and enrolment in cardiac rehabilita-
tion (CR) programs [4-6]. Furthermore, these psycho-
social factors often cluster within an individual with a
significant number of patients presenting with multiple
psychological symptoms upon CR entry [5]. This evi-
dence is particularly concerning as these affective symp-
toms have been shown to increase the risk of primary
and subsequent cardiovascular events, and contribute to
poor behavioural aspects that affect general cardiovascu-
lar health [7-9]. While anxiety and depression are dis-
tinctly separate at a conceptual level, past attempts to
quantify these constructs yielded high degrees of inter-
correlation [10]. This has resulted in the development of
a tripartite continuum with anxiety and depression at
opposite extremes and a centralised nonspecific compo-
nent, which encompasses key aspects of stress [11].
Numerous studies have demonstrated that psycho-
social stress is a significant risk factor for CVD in both
patients with established disease and healthy individuals
[7,12] and large scale community-based studies as well
as prospective studies have found significant relationships
and prevalence rates between anxiety, depression and
CVD risk [13-15]. Whilst the precise physiological and
biochemical mechanisms that underlie the bidirectional
associations between these negative affective states and
CVD are not well understood, a number of studies have
implicated hypothalamic-pituitary-adrenal axis dysfunc-
tion, activation of pro-inflammatory cytokines, autonomic
dysregulation and increased markers of inflammation as
possible key neurobiological mechanisms [16-18]. In
addition to this, previous evidence indicates negative be-
havioural patterns in patients with high anxiety or depres-
sion such as less contact with their cardiologists, being
less likely to seek preventative medical care, poorer medi-
cation compliance as well as reduced self-motivational,
and physical inactivity that further worsens cardiac out-
comes [5,19]. Furthermore, patients with anxiety or de-
pression, even at subclinical levels exhibit significantly
lower quality of life (QoL) scores [5,20].
In an attempt to reduce the prevalence and progression
of CVD, cardiac rehabilitation and prevention programs
which incorporate exercise regimens, stress managementtechniques and patient education, have gained widespread
acceptance and have been shown to improve risk factor
management and functional capacity thereby reducing
the chance of secondary cardiovascular incidences [21].
CR programs have also been shown to improve cognitive
function, QoL, and psychosocial outcomes and programs
with an exercise component also have benefits on mortal-
ity. However in spite of these benefits, CR programs re-
main underutilised with only an estimated 30% of eligible
patients in Australia participating [22,23]. Whilst it is
widely believed that continued exercise and physical activ-
ity is required to sustain most of the benefits gained
through the participation of CR, studies have reported an
adherence rate to physical activity of 30% to 60% in those
who complete phase 2 rehabilitation programs [24,25].
This has been highlighted in a study of myocardial infarc-
tion (MI) patients where CR benefits diminished to a level
in which no significant differences between CR and non-
CR participants could be seen 6 months post-MI [26].
Therefore, a practical adjunct which can improve physio-
logical and psychosocial risk factors may further reduce
cardiac risk factors and improve self-efficacy and long-
term adherence to healthy behaviours.
Yoga may be one such treatment [27]. It is described
as a path, which integrates the body, senses, mind, and
intelligence with the self and numerous studies have re-
ported the benefits of yoga in reducing stress, anxiety,
and depressive symptoms in healthy and psychologically
affected volunteers [28-30]. This is consistent with nu-
merous reviews that highlight the positive potential of
yoga for the treatment of depressive and anxiety disor-
ders [31-34]. Whilst the methodological quality of prior
yoga studies are generally weak, there are multiple re-
views that highlight the favourable effects of yoga in im-
proving the cardiovascular profile across a range of
clinical and healthy populations [35-37]. Significant im-
provements in a wide range of cardiovascular parameters
such as the high frequency component of heart rate vari-
ability (HRV), pulse wave velocity (PWV), blood lipid
profiles (low density / high density lipoproteins and tri-
glycerides), and C-reactive proteins (CRP) highlights the
broad range of effect yoga has on the cardiovascular
system [37-45]. Hatha yoga is consider to achieve bene-
fits in blood circulation by enhance the effect of circula-
tory pumps in the body. Dynamic exercises such as
vinyasas focus on activating and relaxing muscles during
movement to enhance the effects of the musculoskeletal
pump. Furthermore co-activation of antagonistic mus-
cles during vinayasas and static postures (asanas) can
create regions of relatively low and high pressures to
augment muscle co-activation and postural circulation
pumps to improve blood circulation [46].
To complement the array of psychosocial and car-
diovascular impact of yoga, recent studies linking the
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decline of cognitive performance provides a framework
for the investigation into the effects of yoga and its influ-
ence on cognitive function [47-49]. Whilst there are few
studies which assess the effect of yoga on neuro-cognition,
considering its capacity to improve a wide range of car-
diovascular parameters, there may be corresponding im-
provements in the cognitive profile. Preliminary evidence
in a study by Cohen et al. [50] demonstrates a strong asso-
ciation between the executive abilities of focused attention,
processing speed, maintenance of effort, and QoL im-
provements after a yoga intervention in CR patients [50].
Whilst there is a significant body of evidence to support
its use in healthy, psychosocially affected and various
pathological populations, there are relatively few studies
that examine a combination of psychosocial, cardiovascu-
lar, and cognitive effects in cardiac or CR populations.
Given the impact of yoga across a broad range of health
adaptations in various populations, we hypothesise that
yoga will improve anxiety, depression and stress accom-
panied by improvements in cardiovascular parameters of




This is a two arm, multi-centre, parallel-arm randomised
controlled trial that will compare the outcomes of pa-
tients with cardiovascular disease assigned to a 12 week
yoga intervention or to a no-treatment control group.
The study will be conducted in approximately 134 post-
CR participants over a period of 16 weeks comprising of
a 12 week intervention period and 4 week follow up
assessment. The primary outcome of this study is the
component and overall scores obtained through the
Depression Anxiety Stress Subscale (DASS) [51]. Second-
ary outcomes include QoL and cardiovascular and cogni-
tive function. Timepoints for assessments will take place
at baseline (week 0), mid-intervention (week 6), post-
intervention (week 12), and at follow up (week 16). Ethics
approval has been sought from the University of Western
Sydney (H9402), Sydney Adventist Hospital Group (2011.40)
and Western Sydney Local Health District Human Re-
search Ethics Committees (2013/6/4.5(3747)).
Sample size and power calculation
To our knowledge, there is at present only one study
which examines the effect of yoga training in post-CR
patients [52]. This study assessed the effects of a 6 week
yoga program on lipid profiles and brachial artery vaso-
dilation in 10 post-CR patients and 23 healthy individ-
uals however published data was insufficient to conduct
a preliminary power analysis [52]. Given the DASS is a
primary outcome measure in this study, a power analysiswas conducted upon the results published in a meta-
analysis on yogic effects in depression [34]. Results pub-
lished by Cramer et al. [34] noted a standardised mean
difference of 0.69 compared to usual care across five
studies. Application of these findings as a basis for an
approximated power calculation resulted in an estimated
required sample size of 112 participants. Allowing a 20%
drop-out rate, a total of 134 patients will be recruited in
the current study. This power calculation has been con-
ducted based on a population other than post-cardiac re-
habilitation due to a lack of available data in this patient
cohort to permit a more robust calculation. As such, an
interim sample size analysis will also be conducted at
n = 50 allowing for an acceptable estimate of the popula-
tion standard deviation and hence considerably more ro-
bust sample size calculation to ensure adequate power.
Participants
Eligibility criteria includes: Adult (>18 years) having
proven coronary artery disease and completion of a
Phase 2 cardiac rehabilitation program within the past
9 months; available to attend two yoga sessions per week
and complete a simplified self-administered yoga pro-
gram once a week for the duration of the study; not cur-
rently or previous engaged in a yoga program (>3 yoga
session); no acute or chronic medical conditions which
would make yoga potentially hazardous; ability to com-
municate in English; willingness and cognitive ability to
provide written informed consent. Should the participant
have any of the following conditions they will be ex-
cluded from the trial: pacemakers or implanted defibril-
lators, pregnancy; end stage congestive heart failure;
permanent bed-bound status; unstable abdominal, thor-
acic or cerebral aneurysm; acute myocarditis, pericardi-
tis, pulmonary embolus or pulmonary infarction; severe
cognitive deficits (MMSE < 21); previous or current psy-
chological disorders that are not associated with depres-
sion or anxiety.
Randomization
Participants will be randomized via computer-generated
randomly permuted blocks into interventional group or
control group. The randomization assignments will be
prepared by a National Institute of Complementary
Medicine (NICM) Research Program Coordinator who
is external to the research team. Group assignment will
be delivered to participants in sealed envelopes once the
participant is screened and fully enrolled.
Intervention
Experimental group
Participants randomised to the yoga therapy group will
receive two supervised yoga sessions per week for a
period of 12 weeks. They will also be provided with a
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instructed to practice once per week. The yoga sessions
will be group-based and led by an experienced yoga in-
structor from Yoga Synergy Pty Ltd (Sydney, Australia)
[46]. These sessions will run twice per week for approxi-
mately one hour per session (details of yoga sequence
and time requirements outlined in Table 1). The hatha
yoga program will be similar to that used by the research
team in a previous study [45] and will involve teaching
beginner students safely and progressively over 12 weeks
incorporating asanas (poses and postures), pranayamaTable 1 Yoga routine
Introductory section
5 Minutes Utkata Vinyasa




10 Minutes Trikonasa Vinyasa
Parsvakona Vinyasa
Gadja Hasta Padottana Vinyasa









Pada Sirsa Preparation Vinyasa
Back Bending Sequence
5 Minutes Adho Viparita Vinyasa
Adho Viparita Vinyasa
Urdhava Dhanura Vinyasa
Back Bend Releasing Sequence




10 Minutes Sarvangasana Vinyasa
Viparita Mudra Vinyasa
Padma Vinyasa
Pranayam Meditation & Relaxation
15 Minutes Nadi Padma Namaskar
Nadi Sodhana Pranayama
Savaasana(breathing control) and savasana (meditation). At the
start of each session, a series of introductory movements
designed to warm-up the extremities, large joints and
spine (itkata vinyasa and utkata danda nadi vinyasa)
will be conducted before moving into a salute to the
moon (candra namaskar). This will be followed by
standing postures which are linked to one another to
warm up the body whilst stretching and strengthening
the muscles (trikonasa, parsvakona, gadja hasta padot-
tana, gadja baddha padottana, parsvottonasa, eka pada,
virabhadra). Following this, a series of floor postures
which are also linked together will be conducted and in-
clude: forward bends, twists, hip opening, back arches,
and back arch releases. As participants become more
competent with training, an inversion (shoulderstand) is
added to help calm and restore the body and nervous
system. This is followed by a series of neck and spine re-
leases to ensure participant safety. Participants then sat
on the floor and engaged in breathing exercises (prana-
yama) and then supine meditation/relaxation (savasana).
All postures and exercises are comprised of a simple and
more challenging variant to allow difficulty to be scal-
able within the yoga program in relation to participant
ability and capacity.
Control group
Participants randomised to the wait list control group
will receive no instructions about yoga practice for the
16 week trial period (12 week intervention +4 week fol-
low up). Upon their completion of the trial, wait list par-
ticipants will be given the opportunity to participate
within the yoga program.
Outcomes
Participants will be restricted from consuming caffeine
4 hours prior to and alcohol 24 hours prior to each of
the four testing sessions (baseline, mid-intervention,
post-intervention, follow-up). This includes caffeinated
products such as caffeine tablets (No-Doz, etc.) as well
as caffeinated drinks.
Psychological outcomes
Depression Anxiety Stress Scales (DASS)
The DASS is a set of three self-reported scales designed
to assess the negative emotional states of depression,
anxiety and stress. Each of the three DASS sub-scales
contains 14 items, divided into subscales of 2–5 items
with similar content. The DASS has been employed in a
number of studies in cardiac populations and has been
shown to have good test-retest reliability coefficients for
all scales [53]. The DASS scale was found to show better
discrimination when assessed in comparison to a well-
established coronary prone behavioural pattern scale
such as the Framingham Scale in a group of Myocardial
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not as widely used as other questionnaires of anxiety
and depression such as the State Trait Anxiety Inven-
tory, Beck Depression Inventory or Beck Anxiety Inven-
tory, the DASS shows greater discriminant validity in
regards to these psychosocial factors [11]. Participants
will be asked to use 4-point severity/frequency scales to
rate the extent to which they have experienced each
state over the past week. Overall DASS scores will be
calculated and presented for statistical analysis.
Short Form 36 version 2 (SF36v2)
Short Form 36 is a psychometrically robust and clinically
credible 36–item questionnaire that is designed to assess
health related quality of life across diverse medical and
psychiatric groups [55,56]. It has also been shown to be
a valid and reliable instrument for assessing physical and
mental health status of cardiac patients and that CVD is
associated with reductions in health-related QoL [57].
The SF36v2 organises the 36 items into eight compo-
nents and presented on a percentage scale (0–100) and
T-score. These eight components will be combined into
two summary measures to provide overall estimates of
physical and mental health. SF36v2 will be presented to
participant as either a paper based questionnaire or as
an electronic survey using Evado clinical trial software
(Evado, Melbourne, Australia).
Cardiovascular measurements
Heart Rate and Blood Pressure: All blood pressure and
heart rate measurements will be calculated using an
automatic sphygmomanometer, designed for professional
use (Omron, Sydney, Australia). Brachial arterial blood
pressure will be taken following a 5 minute rest period.
This will be done with an automatic sphygmomanom-
eter whilst the participant is sitting comfortably.
Heart Rate Variability (HRV): HRV has been exten-
sively used to assess vagal function and the associations
between autonomic imbalance and disease morbidity
and mortality [58]. To date, there is a large body of evi-
dence indicating that HRV is an independent predictor
of CVD morbidity and mortality in both high and low
risk populations [59-62]. Whilst large population studies
have highlighted this association as early as the 1980s,
recent research has strongly suggests that negative
affective states may significantly impacts on HRV, dis-
ease and poor health [63,64]. Time and frequency do-
mains measurements of HRV have been successfully
used to index vagal activity and although there is debate
regarding the reflection of Parasympathetic Nervous Sys-
tem (PNS) and/or Sympathetic Nervous System (SNS)
influence of low frequency power, high frequency power
has been shown to primarily reflect PNS activity with
consensus amongst numerous studies is that lower indexvalues of vagal function are associated with disease mor-
bidity and mortality [65]. Three electrocardiogram (ECG)
electrode pads will then be placed onto the participant’s
upper left and upper right chest as well the lower left side
of the torso. Participants will be asked to lay supine for
10 minutes during which the SphygmoCor system (AtCor
Medical, Sydney, Australia) will capture data for HRV cal-
culation. Data from both time (standard deviation of R to
R intervals and root mean square successive differences)
and frequency (high and low frequency spectral power
and ratios) domain variables will be collected and ana-
lysed. This will provide indices that reflect the input to the
heart from the two major branches of autonomic nervous
system, the SNS and PNS.
Pulse Wave Velocity (PWV): Pulse Wave Velocity is
generally accepted as the simplest, non-invasive, robust
and reproducible method of determining arterial stiff-
ness [66]. Research indicates it has independent predict-
ive value for cardiovascular mortality and morbidity in a
wide range of pathological and general populations
[67-70]. Non-invasive PWV has been validated against
invasive aortic PWV (correlation coefficient = 0.70) with
suprasternal notch-femoral minus carotid-suprasternal
notch distance showing the best agreement with invasive
data [71]. While the participant is still supine, an ECG-
femoral and carotid tonometric procedure will also be
conducted. PWV procedure will be conducted in accord-
ance to with recommendations outlined in the Expert
Consensus Document on Arterial Stiffness [66]. Travel
distance will be calculated by subtracting the carotid ar-
tery to suprasternal notch distance from the suprasternal
notch to femoral artery. A single high fidelity applana-
tion tonometer will then be placed over carotid and fem-
oral arteries and data will be acquired for PWV. Travel
time between the two arterial sites will be calculated as
the difference between R-waves and the footpoints at
their respective sites [71]. Footprint of the pressure wave
at both sites will be automatically assessed using the
intersecting-tangent method [71]. Calculations will be
completed using SphygmoCor Cardiovascular Manage-
ment Software (AtCor Medical, Sydney, Australia).
Carotid Intima Media Thickness (CIMT): Measure-
ment of CIMT with B-mode ultrasound is a sensitive,
non-invasive and reproducible technique for both identi-
fication and quantification of subclinical vascular disease
and for evaluating CVD risk [72]. Imaging of the carotid
artery to identify areas of increased thickness and non-
occlusive atherosclerotic plaque which represents early
stages of arterial injury and atherosclerosis has increas-
ingly being used as a surrogate cardiovascular endpoint
in a number of clinical trials [73]. Whilst there are nu-
merous reviews and studies providing evidence that
CIMT is strongly related to CVD incidents and that it is
a well validated research tool , variations in methodology
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tion of this technique for routine assessment in clinical
settings [74]. As a result, numerous guideline and con-
sensus statements have been produced in an attempt to
standardise CIMT procedures for research and clinical
use. CIMT procedures in this study will be conducted in
accordance with the Mannheim Carotid Intima-Media
Thickness Consensus (2004–2006) [73]. The participant
will be asked to lie in a supine position with their head
tilted to the side. High resolution B-mode carotid ultra-
sonography will be performed using a 13Mhz linear-
array transducer on a GE Vivid I ultrasound system (GE
Medical, Sydney, Australia). Pre-processing configura-
tions will be held constant during all examinations. The
gain is to be adjusted so that the less dense arterial wall
interface should be just visible and the image should
clear show both near and far vessel walls. The Common
Carotid Artery (CCA) will be insonated longitudinally
and perpendicular to the vessel wall. Measurements are
to be taken from the far wall of the CCA within 10 cm
from the carotid bifurcation and of a minimal measure-
ment length of 10 mm. IMT to be defined as the dis-
tance between the luminal-endothelial interface and the
junction between the media and adventitia. Mean values
of at least 10 measurements at systole are to be used for
measurement. Image sets will be assessed for clarity and
automatic edge tracking software known as EchoPak
(GE Medical, Sydney, Australia) to be used offline to de-
termine averaged mean and maximal IMT values and
adventitia to adventitia diameter.
Cognitive function
Computerised Mental Performance Assessment System
(COMPASS): The Computerised Mental Performance
Assessment System (COMPASS) features a number of
computerised cognitive tasks designed to test various as-
pects of mental function. The COMPASS test battery
has been used in numerous cognitive studies and has
been shown to be sensitive to changes in a number of
cognitive domains [75-77]. The system employs a range
of similarly validated cognitive tasks seen in compu-
terised test suites such as the Cognitive Drug Research
computerised assessment system however COMPASS is
a purposely designed software application allowing for
greater flexibility in choice of tasks and delivery of ran-
domly generated parallel versions of standard cognitive
assessment tasks [78]. Data from alternate forms of each
task presented during testing sessions will be automatic-
ally captured by the COMPASS software.
Biochemistry markers
Low Density Lipoproteins (LDL), High Density Lipopro-
teins (HDL) and Triglycerides: Lipid levels, such as low
High Density Lipoprotein (HDL) and high Low DensityLipoprotein (LDL) and triglyceride levels have been
shown to be associated with increased risk of CVD [79].
Whilst the initiation of atherosclerosis has been long de-
bated, mounting evidence suggests that LDLs interact
with arterial walls allowing for prolonged exposure to
local enzymes, both oxidative and non-, leading to modi-
fications of lipoproteins and their constituents [80].
These modified lipoproteins have been suggested to play
a role in inflammatory reactions that accelerate lesion
development [81]. In contrast, research into HDLs high-
light their functionality as being potentially highly vaso-
protective in inhibiting endothelial apoptosis, maintain
vaso-reactivity, contributing to endothelium repair and
reducing adhesion molecule expression [82]. All of these
actions may attenuate key processes of atherosclerotic
plaque formation. In addition, population studies that
provide evidence of associations between low HDLs and
CVD risk are strong and consistent [79,83]. Lipid pro-
files will be determined before and after the intervention
at weeks 0 and 12. Participants will be sent to have
blood samples taken and pathology testing conducted by
a reputable pathology collection centre.
Glucose: Similarly to cholesterol, plasma glucose levels
have been observed to be a continuous risk factor for
CVD with diabetic patients exhibiting at least a 2-fold in-
crease in risk [84]. However as traditional glucose cut off
levels were chosen to identify diabetes mellitus and not in-
creased CVD risk, people with elevated but below diabetic
glucose concentrations still represent increased risk which
has been highlighted in several large population studies
[85-87]. Glucose profiles will be determined before and
after the intervention at weeks 0 and 12. Participants will
be sent to have blood samples taken and pathology testing
conducted by a reputable pathology collection centre.
C-reactive protein (CRP): C-Reactive protein (CRP)
was initially used as a non-specific biomarker for inflam-
matory processes however has become a powerful inde-
pendent modifiable predictor of CVD in various clinical
and non-clinical populations [88,89]. The Centre for
Disease Control and Prevention and the American Heart
Association have issued a Class IIa recommendation that
screening of CRP be a routine part of a patient’s global
cardiovascular risk assessment and in primary preven-
tion, CRP adds prognostic value to all levels of Framing-
ham risk [90]. In addition to this, CRP was found to be a
stronger predictor of CVD incidences that low density
lipid levels [91]. CRP will be determined before and after
the intervention at weeks 0 and 12. Participants will be
sent to have blood samples taken and pathology testing
conducted by a reputable pathology collection centre.
Participant diary
Participants will also be asked to complete a weekly diary
documenting drastic changes in diet, commencement or
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tion and smoking, number of hours spent exercising,
changes in medication, significant positive or negative life
events, adverse events, and compliance to yoga program.
These behaviours will be monitored by open-ended ques-
tions to be completed weekly. This data will be presented
for a descriptive synthesis only with compliance to yoga
sessions and adverse events, coded into a binary yes/no
format, to be considered for inclusion in analysis of covari-
ance (ANCOVA) models as covariates.
Safety and adherence
In addition to data collected from participant diaries,
each assessment visit will detail any information pertain-
ing to adverse events and yoga session compliance will
be monitored through class attendance. As stated previ-
ously, this data will be included for ANCOVA models as
covariates.
Statistical analysis
Analysis is to be performed using the R statistics pack-
age (version 3.1.1). All data will be inspected visually
and statistically for normality (skewness and kurtosis be-
tween −1 and +1). Analysis of variance (ANOVA) and
chi-squared tests of independence will be used to check
for any differences between groups at study entry, any
differences found here will be controlled for in that out-
come analysis. Outcome analysis will take the form of
ANCOVAs to detect changes between the experimental
and control groups at post- treatment while controlling
for baseline values and other possible confounders such
as age, gender, time since cardiac incident, time since
phase-2 CR completion and current exercise regimen or
phase-3 CR participation. Multiple imputations will be
used to impute missing data for participants with less
than 10% missing data. An intention to treat analysis in
which all missing data will be managed with multiple
imputations will be conducted along with a separate per
protocol analysis in which those with greater than 10%
missing data or less than 60% yoga session attendance
will be excluded. A p-value of less than 0.05 will be con-
sidered statistically significant.
Discussion
Secondary prevention is an integral aspect regarding the
comprehensive care of patients with CVD. Although it
has been shown that CR is effective in positively modify-
ing cardiac risk factors and reducing subsequent cardiac
mortality, these benefits appear to plateau and gradually
decrease upon completion of CR [92]. As noted by
Gupta et al. [93] benefits achieved during CR programs
are potentially sustainable at a one year follow up, how-
ever, minimal improvement across outcome measures was
noted and significant regression was seen in importantvariables such as 6-minute walk distance, body mass
index, diet scores, and smoking status. This is corrobo-
rated by evidence from Willich et al. [94] and Boesch et al.
[95] who also reported worsening of lipid control at long-
term follow points. According to adherence reports by
Bittner et al. [96] and Ljubic et al. [97], approximately 50%
of CR graduates do not maintain adherence to regular
physical activity 5–6 months post-phase 2 CR and further
highlights that this poor adherence may be associated with
higher levels of psychosocial distress such as depression,
anxiety, and stress. Given that numerous studies emphasis
the capacity of yoga in positively modifying cardiovascular
risk factors [35,36,38-45] in addition to psychosocial attenu-
ation [28-34,98], its application in post-cardiac rehabilita-
tion may assist in sustaining and further supplementing
the beneficial effects of phase 2 CR. As such, this study
will aim to determine the effect of yoga practice on psy-
chosocial, cardiovascular and cognitive function in post-
phase 2 cardiac rehabilitation patients and is expected to
provide insight into the short term impact of yoga on trad-
itional and relatively novel cardiovascular risk factors and
prognostic markers. In addition, these findings may also
provide evidence supporting the incorporation of yoga
into standardised CR programs as a practical adjunct to
improve the management of psychosocial symptoms asso-
ciated with CV events in addition to improving patients’
cognitive and cardiovascular functions.
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